Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13;16(8):e66824.
doi: 10.7759/cureus.66824. eCollection 2024 Aug.

Clinical and Functional Outcomes of Platelet-Rich Plasma Injection and Corticosteroid Injection in Patients With De Quervain's Tenosynovitis: A Comparative Retrospective Study

Affiliations

Clinical and Functional Outcomes of Platelet-Rich Plasma Injection and Corticosteroid Injection in Patients With De Quervain's Tenosynovitis: A Comparative Retrospective Study

Rohith C Sunil et al. Cureus. .

Abstract

Background and aim De Quervain's tenosynovitis (DQST) is a prevalent condition involving tendon inflammation in the wrist. This study compares the clinical and functional outcomes between patients receiving platelet-rich plasma (PRP) injections and those receiving corticosteroid injections for DQST. Methods A retrospective study conducted at Sri Devaraj Urs Academy of Higher Education and Research, Kolar, India, included 58 patients with DQST, divided into Group A (PRP injection) and Group B (corticosteroid injection). Assessments were conducted using the Visual Analogue Scale (VAS), the Disabilities of the Arm, Shoulder, and Hand (DASH) score, and the Modified Mayo Wrist Score (MMWS) at baseline, one month, three months, and six months. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (Released 2013; IBM Corp., Armonk, NY, USA), with significance set at p < 0.05. Results Both treatment groups demonstrated a reduction in VAS scores over time. Significant improvements were observed at one month (p = 0.007) and six months (p = 0.004) post-injection. Baseline (p = 0.336) and three-month (p = 0.829) VAS scores showed no significant differences. Similarly, DASH scores were not significantly different at any measured time points: baseline (p = 0.331), one month (p = 0.592), three months (p = 0.707), and six months (p = 0.314). MMWS scores also showed no significant differences at baseline (p = 0.123), one month (p = 0.101), three months (p = 0.422), and six months (p = 0.956). Independent sample t-tests highlighted significant VAS score improvements at one month (t = 2.813, p = 0.007) and six months (t = -3.009, p = 0.004), but DASH and MMWS scores showed no significant differences at any time points. Chi-square tests indicated no significant associations between the groups at one-month, three-month, and six-month follow-ups. Conclusion Both PRP and corticosteroid injections effectively alleviate pain in DQST patients, as evidenced by significant VAS score improvements. However, functional outcomes measured by DASH and MMWS scores did not significantly differ between the treatments. These results suggest that while both treatments are effective for pain management, their short-term impact on functional improvement may be similar. To investigate long-term functional results, more research with bigger sample sizes and longer follow-up periods is required.

Keywords: clinical outcomes; comparative study; corticosteroid injection; de quervain’s tenosynovitis; functional outcomes; musculoskeletal disorders; platelet-rich plasma (prp) injection; treatment efficacy.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Sri Devaraj Urs Academy of Higher Education and Research issued approval SDUAHER/KLR/R&D/CEC/S/PG/13/2024-25. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Systematic review and meta-analysis on the work-related cause of de Quervain tenosynovitis: a critical appraisal of its recognition as an occupational disease. Stahl S, Vida D, Meisner C, Lotter O, Rothenberger J, Schaller HE, Stahl AS. Plast Reconstr Surg. 2013;132:1479–1491. - PubMed
    1. DeQuervain tenosynovitis in pregnant and postpartum women. Schned ES. Obstet Gynecol. 1986;68:411–414. - PubMed
    1. Treatment of de Quervain’s disease: role of conservative management. Lane LB, Boretz RS, Stuchin SA. J Hand Surg Br. 2001;26:258–260. - PubMed
    1. Corticosteroid injection for de Quervain's tenosynovitis. Peters-Veluthamaningal C, van der Windt DA, Winters JC, Meyboom-de Jong B. Cochrane Database Syst Rev. 2009:0. - PubMed
    1. A critical review of visual analogue scales in the measurement of clinical phenomena. Wewers ME, Lowe NK. Res Nurs Health. 1990;13:227–236. - PubMed

LinkOut - more resources